A phase I, open-label, dose escalation and expansion study is currently recruiting patients to evaluate the safety, tolerability, and preliminary clinical activity of FHD-609 for patients with advanced synovial sarcoma or advanced SMARCB1-loss tumors (ClinicalTrials.gov Identifier: NCT04965753). Here, SMARCB1 is linked to synovial sarcoma.